Cargando…
A Case of Binocular Metastatic Choroidal Tumor Originating from Pulmonary Adenocarcinoma Successfully Treated with Molecular Target Therapy
The occurrence of ocular metastasis from lung cancer is uncommon. In our current case, we report on a 64-year-old male patient found to have metastatic lesions in both choroids after being diagnosed with lung adenocarcinoma. As the patient was found to have a mutation in the epidermal growth factor...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
S. Karger AG
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10601831/ https://www.ncbi.nlm.nih.gov/pubmed/37901630 http://dx.doi.org/10.1159/000530130 |
_version_ | 1785126272802750464 |
---|---|
author | Yamaoka, Masataka Igarashi, Tsutomu Shiratori, Naka Miyadera, Keiki Sugano, Teppei Noro, Rintaro Takahashi, Hiroshi |
author_facet | Yamaoka, Masataka Igarashi, Tsutomu Shiratori, Naka Miyadera, Keiki Sugano, Teppei Noro, Rintaro Takahashi, Hiroshi |
author_sort | Yamaoka, Masataka |
collection | PubMed |
description | The occurrence of ocular metastasis from lung cancer is uncommon. In our current case, we report on a 64-year-old male patient found to have metastatic lesions in both choroids after being diagnosed with lung adenocarcinoma. As the patient was found to have a mutation in the epidermal growth factor receptor (EGFR), he was treated with the EGFR tyrosine kinase inhibitor (EGFR TKI), afatinib. However, the treatment response suggested the presence of a progressive disease. Thus, due to cancerous meningitis, the patient’s treatment was changed from afatinib to erlotinib, in addition to adding bevacizumab. Although the general condition of the patient did not change, improvement was noted for the choroidal metastasis. Moreover, the drug change also resulted in an improvement of the visual power of both eyes. Therefore, the results for this patient suggest that systemic administration of erlotinib and bevacizumab may be an effective treatment that leads to morphological and functional improvement in choroidal metastasis cases. |
format | Online Article Text |
id | pubmed-10601831 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | S. Karger AG |
record_format | MEDLINE/PubMed |
spelling | pubmed-106018312023-10-27 A Case of Binocular Metastatic Choroidal Tumor Originating from Pulmonary Adenocarcinoma Successfully Treated with Molecular Target Therapy Yamaoka, Masataka Igarashi, Tsutomu Shiratori, Naka Miyadera, Keiki Sugano, Teppei Noro, Rintaro Takahashi, Hiroshi Case Rep Ophthalmol Case Report The occurrence of ocular metastasis from lung cancer is uncommon. In our current case, we report on a 64-year-old male patient found to have metastatic lesions in both choroids after being diagnosed with lung adenocarcinoma. As the patient was found to have a mutation in the epidermal growth factor receptor (EGFR), he was treated with the EGFR tyrosine kinase inhibitor (EGFR TKI), afatinib. However, the treatment response suggested the presence of a progressive disease. Thus, due to cancerous meningitis, the patient’s treatment was changed from afatinib to erlotinib, in addition to adding bevacizumab. Although the general condition of the patient did not change, improvement was noted for the choroidal metastasis. Moreover, the drug change also resulted in an improvement of the visual power of both eyes. Therefore, the results for this patient suggest that systemic administration of erlotinib and bevacizumab may be an effective treatment that leads to morphological and functional improvement in choroidal metastasis cases. S. Karger AG 2023-09-08 /pmc/articles/PMC10601831/ /pubmed/37901630 http://dx.doi.org/10.1159/000530130 Text en © 2023 The Author(s). Published by S. Karger AG, Basel https://creativecommons.org/licenses/by-nc/4.0/This article is licensed under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC) (http://www.karger.com/Services/OpenAccessLicense). Usage and distribution for commercial purposes requires written permission. |
spellingShingle | Case Report Yamaoka, Masataka Igarashi, Tsutomu Shiratori, Naka Miyadera, Keiki Sugano, Teppei Noro, Rintaro Takahashi, Hiroshi A Case of Binocular Metastatic Choroidal Tumor Originating from Pulmonary Adenocarcinoma Successfully Treated with Molecular Target Therapy |
title | A Case of Binocular Metastatic Choroidal Tumor Originating from Pulmonary Adenocarcinoma Successfully Treated with Molecular Target Therapy |
title_full | A Case of Binocular Metastatic Choroidal Tumor Originating from Pulmonary Adenocarcinoma Successfully Treated with Molecular Target Therapy |
title_fullStr | A Case of Binocular Metastatic Choroidal Tumor Originating from Pulmonary Adenocarcinoma Successfully Treated with Molecular Target Therapy |
title_full_unstemmed | A Case of Binocular Metastatic Choroidal Tumor Originating from Pulmonary Adenocarcinoma Successfully Treated with Molecular Target Therapy |
title_short | A Case of Binocular Metastatic Choroidal Tumor Originating from Pulmonary Adenocarcinoma Successfully Treated with Molecular Target Therapy |
title_sort | case of binocular metastatic choroidal tumor originating from pulmonary adenocarcinoma successfully treated with molecular target therapy |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10601831/ https://www.ncbi.nlm.nih.gov/pubmed/37901630 http://dx.doi.org/10.1159/000530130 |
work_keys_str_mv | AT yamaokamasataka acaseofbinocularmetastaticchoroidaltumororiginatingfrompulmonaryadenocarcinomasuccessfullytreatedwithmoleculartargettherapy AT igarashitsutomu acaseofbinocularmetastaticchoroidaltumororiginatingfrompulmonaryadenocarcinomasuccessfullytreatedwithmoleculartargettherapy AT shiratorinaka acaseofbinocularmetastaticchoroidaltumororiginatingfrompulmonaryadenocarcinomasuccessfullytreatedwithmoleculartargettherapy AT miyaderakeiki acaseofbinocularmetastaticchoroidaltumororiginatingfrompulmonaryadenocarcinomasuccessfullytreatedwithmoleculartargettherapy AT suganoteppei acaseofbinocularmetastaticchoroidaltumororiginatingfrompulmonaryadenocarcinomasuccessfullytreatedwithmoleculartargettherapy AT nororintaro acaseofbinocularmetastaticchoroidaltumororiginatingfrompulmonaryadenocarcinomasuccessfullytreatedwithmoleculartargettherapy AT takahashihiroshi acaseofbinocularmetastaticchoroidaltumororiginatingfrompulmonaryadenocarcinomasuccessfullytreatedwithmoleculartargettherapy AT yamaokamasataka caseofbinocularmetastaticchoroidaltumororiginatingfrompulmonaryadenocarcinomasuccessfullytreatedwithmoleculartargettherapy AT igarashitsutomu caseofbinocularmetastaticchoroidaltumororiginatingfrompulmonaryadenocarcinomasuccessfullytreatedwithmoleculartargettherapy AT shiratorinaka caseofbinocularmetastaticchoroidaltumororiginatingfrompulmonaryadenocarcinomasuccessfullytreatedwithmoleculartargettherapy AT miyaderakeiki caseofbinocularmetastaticchoroidaltumororiginatingfrompulmonaryadenocarcinomasuccessfullytreatedwithmoleculartargettherapy AT suganoteppei caseofbinocularmetastaticchoroidaltumororiginatingfrompulmonaryadenocarcinomasuccessfullytreatedwithmoleculartargettherapy AT nororintaro caseofbinocularmetastaticchoroidaltumororiginatingfrompulmonaryadenocarcinomasuccessfullytreatedwithmoleculartargettherapy AT takahashihiroshi caseofbinocularmetastaticchoroidaltumororiginatingfrompulmonaryadenocarcinomasuccessfullytreatedwithmoleculartargettherapy |